Alzheimer disease (AD) and other forms of dementia pose serious challenges to patients, caregivers, and healthcare systems worldwide. As populations age, the global prevalence of dementia is expected to triple to 132 million by 2050. And in the United States alone, the costs of AD are projected to grow by 400% from US $186 billion in 2018 to US $750 billion in 2050.
Cognitive decline can go undetected for long periods of time because the disease has a prolonged preclinical phase, during which neuronal and neurobiological changes can occur for years or decades before noticeable symptoms appear. Early detection of symptoms is important, but there is currently not enough clinical infrastructure to meet the demand for in-person screening. Digital technology represents an inexpensive and readily available option to enhance the data collection of human cognition or activities which are associated with cognition, as well as the way in which we communicate and interact with healthcare professionals.
The goal of this Research Topic is to evaluate and publish papers related to technological enhancements in cognitive assessment or cognition-related activities and healthcare access. Ultimately, we want to highlight the way that technology is transforming the field of cognitive health across the patient journey.
We welcome submissions from all researchers conducting scientific work in the intersection of technology and cognitive health. Possible themes can include but are not limited to:
- Novel methods/ techniques for collecting cognitive data through hardware or software innovations
- New or adapted biomarkers that can relate to or predict areas of cognitive decline
- Risk reduction of cognitive decline through lifestyle intervention or other non-pharmacological models
- Enhanced patient - physician interactions through telehealth or related methods
- Gaming and/ or social innovations to help isolated individuals at risk for cognitive disease development
All manuscript types will be considered, however, the highest priority will be given to original research, all types of reviews, and methods articles.
--
Jordan Glenn is the Senior Vice President of Neurotrack Technologies. John Harrison has served as consultant for multiple private firms, including companies such as AlzeCure, MyCognition and Neurotrack. All other Topic Editors declare no conflicts of interest.
Alzheimer disease (AD) and other forms of dementia pose serious challenges to patients, caregivers, and healthcare systems worldwide. As populations age, the global prevalence of dementia is expected to triple to 132 million by 2050. And in the United States alone, the costs of AD are projected to grow by 400% from US $186 billion in 2018 to US $750 billion in 2050.
Cognitive decline can go undetected for long periods of time because the disease has a prolonged preclinical phase, during which neuronal and neurobiological changes can occur for years or decades before noticeable symptoms appear. Early detection of symptoms is important, but there is currently not enough clinical infrastructure to meet the demand for in-person screening. Digital technology represents an inexpensive and readily available option to enhance the data collection of human cognition or activities which are associated with cognition, as well as the way in which we communicate and interact with healthcare professionals.
The goal of this Research Topic is to evaluate and publish papers related to technological enhancements in cognitive assessment or cognition-related activities and healthcare access. Ultimately, we want to highlight the way that technology is transforming the field of cognitive health across the patient journey.
We welcome submissions from all researchers conducting scientific work in the intersection of technology and cognitive health. Possible themes can include but are not limited to:
- Novel methods/ techniques for collecting cognitive data through hardware or software innovations
- New or adapted biomarkers that can relate to or predict areas of cognitive decline
- Risk reduction of cognitive decline through lifestyle intervention or other non-pharmacological models
- Enhanced patient - physician interactions through telehealth or related methods
- Gaming and/ or social innovations to help isolated individuals at risk for cognitive disease development
All manuscript types will be considered, however, the highest priority will be given to original research, all types of reviews, and methods articles.
--
Jordan Glenn is the Senior Vice President of Neurotrack Technologies. John Harrison has served as consultant for multiple private firms, including companies such as AlzeCure, MyCognition and Neurotrack. All other Topic Editors declare no conflicts of interest.
